Vir Biotechnology Inc (VIR) Stock Price, Quote & News

Company Profile

Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibod...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 906 4324

Website: www.vir.bio

Address:

1800 Owens Street, Suite 900, San Francisco, United States

S_Franconi May. 16 at 2:02 PM

$VIR

0 · Reply

Dunnieboy1 May. 16 at 6:48 AM

$VIR Softbank have reduced their stake in Vir from around 10% to 6.5%, Softbank announced last year they were reducing stakes in certain sectors to concentrate on Ai investments, doesn’t help large selling on the sp.

0 · Reply

triangkle May. 15 at 10:21 PM

$VIR next catalyst May 29

0 · Reply

jewell69 May. 14 at 1:47 PM

$VIR re entry 9.03 600 2 bad we don’t own any $ONDS right f. Now. It is up 10% Last week We thought $IYZ wasn’t the best comm and telecom because it was 18% of the portfolio was in $CSCO Can somebody help me: $RONB has 2 variations of spaceX (private) that up to about 7.3% of the portfolio. If it is, INDEED a true etf, if the etf gets bigger, does Mr. Ron Baron have more shares to put in the portfolio ….. or NOT ? If the latter, then the percentage of spaceX will decrease ? Please help me to understand this. It wouldn’t be such a puzzle for me if it was a ClOSED END fund.

1 · Reply

VIR_Tical1 May. 14 at 11:22 AM

$VIR https://www.linkedin.com/posts/nasdaq-exchange_it-allows-us-to-take-a-moment-which-we-activity-7459663622412161024-iDRe?utm_source=share&utm_medium=member_ios&rcm=ACoAAAYLhRQB-IOGGhAT3xXNABF9cpcKul_ZvO8

0 · Reply

Dunnieboy1 May. 13 at 10:43 AM

$VIR It's been a mediocre week for Vir Biotechnology, Inc. (NASDAQ:VIR) shareholders, with the stock dropping 10% to US$9.12 in the week since its latest first-quarter results. It was a pretty bad result overall, with revenues coming in 100% lower than the analysts predicted. That was copied from Yahoo and shows how crap some of these ’financial journalist’s’ are saying revenues are 100% down, what revenues? the only money coming in is normally from grants from the Gates Foundation or some stage payments from deals, they don’t mention that this quarter we receive over $350M from the Astellas deal.

2 · Reply

jewell69 May. 12 at 4:22 PM

3 trades, so far tuesday 5/12/26 $ONDS $VIR $NTLA 05/12/2026 Buy NTLA INTELLIA THERAPEUTICS IN 500 $13.65 -$6,825.00 More 05/12/2026 Buy ONDS ONDAS INC 600 $8.94 -$5,364.00 More 05/12/2026 Buy VIR VIR BIOTECHNOLOGY INC 400 $9.26 -$3,704.00

0 · Reply

jewell69 May. 12 at 3:43 PM

$VIR TRING 2 BUY 400 AT 9.26 NOW B A .26 x .28 at 11:43 am edt also looking at $NTLA

0 · Reply

cloudhedge May. 9 at 3:59 PM

$VIR just confirmed an oral session at the EASL Congress (May 27-30) to present the full Week 96 Phase 2 SOLSTICE data in CHD. Big clinical milestone to watch this month. Financials are looking sturdy with $809M cash as of Q1, plus the $315M expected from Astellas in Q2. Cash runway now extends into 2H28. HCW currently has a $20 price target on the stock. With high-value catalysts approaching in both oncology and HDV, the risk/reward setup is definitely grabbing attention at these levels.

0 · Reply

Ce75 May. 8 at 6:44 PM

$VIR At EASL, in addition to the Vir Solstice, data from Mirum Azure-1 Phase 2b will also be presented. This trial, with very strong data and a direct competitor, also has an advantage. Another advantage of Mirum is that it's a monotherapy, making it simpler and potentially less expensive. These will be truly decisive days! What do you think? I'm a little scared.😬

1 · Reply

Vir Biotechnology Transcript: Bank of America Global Healthcare Conference 2026

2026-05-08T14:13:29.000Z - 9 days ago

Vir Biotechnology price target lowered to $23 from $24 at Morgan Stanley

2026-05-07T00:48:04.000Z - 10 days ago

Vir Biotechnology reports Q1 EPS (85c) vs. (88c) last year

May 6, 2026, 4:30 PM EDT - 11 days ago

Vir Biotechnology Earnings Call Transcript: Q1 2026

May 6, 2026, 4:05 PM EDT - 11 days ago

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2026 Financial Results

May 5, 2026, 4:05 PM EDT - 12 days ago

Vir Biotechnology to Participate in Bank of America Securities 2026 Healthcare Conference

Apr 23, 2026, 4:05 PM EDT - 24 days ago

Vir Biotechnology to Host Conference Call for First Quarter 2026 Financial Results

2026-04-16T13:17:10.000Z - 4 weeks ago

Vir Biotechnology closes global collaboration agreement with Astellas Pharma

SNY

Apr 16, 2026, 8:05 AM EDT - 4 weeks ago

Vir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatment of Prostate Cancer

2026-04-13T12:40:25.000Z - 4 weeks ago

Vir Biotechnology announces first patient dosed in Phase 1 trial of VIR-5500

Apr 13, 2026, 8:05 AM EDT - 4 weeks ago

Vir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-targeted, PRO-XTEN® Dual-masked T-cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer

Mar 10, 2026, 1:40 PM EDT - 2 months ago

Vir Biotechnology Transcript: Leerink Global Healthcare Conference 2026

2026-03-04T11:16:01.000Z - 2 months ago

Vir Biotechnology price target raised to $20 from $15 at H.C. Wainwright

Mar 2, 2026, 3:10 PM EST - 2 months ago

Vir Biotechnology Transcript: TD Cowen 46th Annual Health Care Conference

Feb 26, 2026, 4:05 PM EST - 2 months ago

Vir Biotechnology to Participate in Upcoming Investor Conferences

2026-02-26T11:16:17.000Z - 2 months ago

Vir Biotechnology 17.65M share Secondary priced at $8.50

Feb 25, 2026, 10:31 PM EST - 2 months ago

Vir Biotechnology Announces Pricing of Public Offering of Common Stock

2026-02-24T21:36:44.000Z - 2 months ago

Vir Biotechnology announces $200M public offering of common stock

Feb 24, 2026, 4:05 PM EST - 2 months ago

Vir Biotechnology Announces Proposed Public Offering of Common Stock

2026-02-24T19:25:40.000Z - 2 months ago

Vir Biotechnology price target raised to $30 from $26 at Barclays

2026-02-24T14:37:22.000Z - 2 months ago

Vir Biotechnology price target raised to $18 from $14 at Needham

2026-02-24T13:19:50.000Z - 2 months ago

Why Is Vir Biotechnology Stock Up Today?

2026-02-24T13:07:57.000Z - 2 months ago

Vir Biotechnology price target raised to $18 from $12 at Evercore ISI

2026-02-24T12:07:35.000Z - 2 months ago

Vir Biotechnology price target raised to $17 from $13 at BofA

2026-02-24T11:50:12.000Z - 2 months ago

Vir Biotechnology price target raised to $24 from $20 at Morgan Stanley

2026-02-24T11:10:14.000Z - 2 months ago

Vir Biotechnology upgraded to Strong Buy from Outperform at Raymond James

Feb 24, 2026, 4:10 AM EST - 2 months ago

What's Happening With VIR Stock?

Feb 23, 2026, 5:30 PM EST - 2 months ago

Vir Biotechnology Earnings Call Transcript: Q4 2025

2026-02-23T22:20:15.000Z - 2 months ago

Vir Biotechnology reports Q4 EPS (31c), consensus (50c)

Feb 23, 2026, 5:14 PM EST - 2 months ago

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

2026-02-23T22:10:34.000Z - 2 months ago

Vir Biotechnology reports new VIR-5500 data

Feb 23, 2026, 5:08 PM EST - 2 months ago

Astellas collaborates with Vir to develop its experimental prostate cancer drug

2026-02-23T22:05:13.000Z - 2 months ago

Astellas, Vir announce global strategic collaboration

Feb 23, 2026, 5:02 PM EST - 2 months ago

Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer

Feb 23, 2026, 5:00 PM EST - 2 months ago

Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer

Feb 9, 2026, 4:05 PM EST - 3 months ago

Vir Biotechnology to Host Conference Call for Fourth Quarter and Full Year 2025 Financial Results

Jan 14, 2026, 6:45 PM EST - 4 months ago

Vir Biotechnology Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 8:00 AM EST - 4 months ago

Vir Biotechnology Provides Updates on Chronic Hepatitis Delta and Oncology Programs and Upcoming 2026 Clinical Milestones

Jan 5, 2026, 4:05 PM EST - 4 months ago

Vir Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 16, 2025, 4:05 PM EST - 5 months ago

Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing ECLIPSE Clinical Development Program

Dec 3, 2025, 10:50 AM EST - 5 months ago

Vir Biotechnology Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 19, 2025, 4:05 PM EST - 6 months ago

Vir Biotechnology to Participate in the 8th Annual Evercore Healthcare Conference

Nov 18, 2025, 9:00 AM EST - 6 months ago

Vir Biotechnology Transcript: Jefferies London Healthcare Conference 2025

Nov 9, 2025, 6:07 PM EST - 6 months ago

Vir Biotechnology Announces AASLD The Liver Meeting® Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver High Rates of Undetectable HDV RNA with Favorable Safety Profile

Nov 7, 2025, 9:00 AM EST - 6 months ago

Vir Biotechnology to Participate in the Jefferies 2025 London Healthcare Conference

Nov 5, 2025, 4:30 PM EST - 6 months ago

Vir Biotechnology Earnings Call Transcript: Q3 2025

Nov 5, 2025, 4:05 PM EST - 6 months ago

Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Nov 3, 2025, 8:00 AM EST - 6 months ago

Vir Biotechnology Announces Completion of Enrollment in ECLIPSE 1 Phase 3 Trial for Chronic Hepatitis Delta

Oct 22, 2025, 4:05 PM EDT - 7 months ago

Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2025 Financial Results on November 5, 2025

Oct 9, 2025, 4:05 PM EDT - 7 months ago

Vir Biotechnology Announces First Patient Dosed in Part 3 of Phase 1 Trial of PSMA-Targeting PRO-XTEN® Dual-Masked T-Cell Engager VIR-5500 in Combination with Androgen Receptor Pathway Inhibitors for the Treatment of Metastatic Prostate Cancer

Oct 7, 2025, 8:00 AM EDT - 7 months ago

Vir Biotechnology to Present Week 48 SOLSTICE Clinical Results in Hepatitis Delta at AASLD's The Liver Meeting® 2025

Aug 25, 2025, 4:05 PM EDT - 9 months ago

Vir Biotechnology to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Aug 6, 2025, 4:30 PM EDT - 10 months ago

Vir Biotechnology Earnings Call Transcript: Q2 2025

Aug 6, 2025, 4:05 PM EDT - 10 months ago

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Aug 6, 2025, 8:05 AM EDT - 10 months ago

Vir Biotechnology Successfully Initiates all Trials in ECLIPSE Registrational Program for Chronic Hepatitis Delta

Jul 31, 2025, 8:05 AM EDT - 10 months ago

Vir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program for Chronic Hepatitis Delta

Jul 24, 2025, 8:05 AM EDT - 10 months ago

Vir Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of EGFR-Targeting PRO-XTEN™ Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid Tumors

Jul 22, 2025, 4:05 PM EDT - 10 months ago

Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2025 Financial Results on August 6, 2025

Jun 11, 2025, 7:00 AM EDT - 1 year ago

20 stocks you should avoid — no matter how well the market does

CORT CPRX CRK CRNC DDD LUMN LYV

May 28, 2025, 4:05 PM EDT - 1 year ago

Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025

May 27, 2025, 4:30 PM EDT - 1 year ago

Vir Biotechnology Transcript: TD Cowen's 6th Annual Oncology Innovation Summit

May 20, 2025, 4:05 PM EDT - 1 year ago

Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit

May 14, 2025, 4:40 PM EDT - 1 year ago

Vir Biotechnology Transcript: BofA Securities 2025 Healthcare Conference

May 12, 2025, 4:05 PM EDT - 1 year ago

Vir Biotechnology to Participate in Bank of America Securities 2025 Healthcare Conference

May 9, 2025, 6:00 AM EDT - 1 year ago

Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study

May 7, 2025, 4:30 PM EDT - 1 year ago

Vir Biotechnology Earnings Call Transcript: Q1 2025

May 7, 2025, 4:05 PM EDT - 1 year ago

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results

Apr 30, 2025, 4:05 PM EDT - 1 year ago

Vir Biotechnology to Provide Corporate Update and Report First Quarter 2025 Financial Results on May 7, 2025

Apr 24, 2025, 9:30 AM EDT - 1 year ago

Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025

Mar 21, 2025, 7:10 AM EDT - 1 year ago

Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results

Mar 13, 2025, 8:05 AM EDT - 1 year ago

Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta

Feb 26, 2025, 4:30 PM EST - 1 year ago

Vir Biotechnology Earnings Call Transcript: Q4 2024

Feb 26, 2025, 4:05 PM EST - 1 year ago

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 19, 2025, 4:05 PM EST - 1 year ago

Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference

Feb 12, 2025, 4:05 PM EST - 1 year ago

Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

Jan 14, 2025, 7:30 PM EST - 1 year ago

Vir Biotechnology Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 8, 2025, 8:00 AM EST - 1 year ago

Vir Biotechnology Transcript: Status Update

Jan 8, 2025, 7:45 AM EST - 1 year ago

Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC

Dec 18, 2024, 9:30 AM EST - 1 year ago

Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 12, 2024, 4:05 PM EST - 1 year ago

Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta

Dec 3, 2024, 9:10 AM EST - 1 year ago

Vir Biotechnology Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference

Nov 26, 2024, 9:30 AM EST - 1 year ago

Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN™ Masked T-Cell Engager Programs

Nov 25, 2024, 9:30 AM EST - 1 year ago

Vir Biotechnology to Participate in the 7th Annual Evercore ISI HealthCONx Conference

Nov 19, 2024, 8:15 AM EST - 1 year ago

Vir Biotechnology Transcript: Status Update

Nov 18, 2024, 9:15 PM EST - 1 year ago

Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program

S_Franconi May. 16 at 2:02 PM

$VIR

0 · Reply

Dunnieboy1 May. 16 at 6:48 AM

0 · Reply

triangkle May. 15 at 10:21 PM

$VIR next catalyst May 29

0 · Reply

jewell69 May. 14 at 1:47 PM

1 · Reply

VIR_Tical1 May. 14 at 11:22 AM

0 · Reply

Dunnieboy1 May. 13 at 10:43 AM

2 · Reply

jewell69 May. 12 at 4:22 PM

0 · Reply

jewell69 May. 12 at 3:43 PM

$VIR TRING 2 BUY 400 AT 9.26 NOW B A .26 x .28 at 11:43 am edt also looking at $NTLA

0 · Reply

cloudhedge May. 9 at 3:59 PM

0 · Reply

Ce75 May. 8 at 6:44 PM

1 · Reply

biochirp May. 7 at 5:43 PM

$VIR ER was that bad?

1 · Reply

jewell69 May. 7 at 3:59 PM

$VIR Ohhh, the joy and confidence that comes from petting stray dogs and talking to the elderly ! 05/07/2026 Buy VIR VIR BIOTECHNOLOGY INC 400 $9.485 -$3,794.00 More 05/05/2026 Sell VIR VIR BIOTECHNOLOGY INC 700 $10.005 $0.28 $7,003.22 More 05/05/2026 Buy VIR VIR BIOTECHNOLOGY INC 700 $9.9455 -$6,961.85 More Total $0.28 -$3,752.63

0 · Reply

Dunnieboy1 May. 7 at 2:42 PM

$VIR back down below $10, that will be people reading the headline of the results but not reading through them, for example the revenue is down year on year but the Astellas money $350M doesn’t get paid to us till this quarter.

1 · Reply

metalcook May. 7 at 5:01 AM

$VIR first time VIR-5818 is mentioned as a combo in a press release and ongoing. Where is mono data update?

1 · Reply

McMillion1 May. 6 at 11:39 PM

$VIR any educated view on the reported earnings?

0 · Reply

mikesterz7 May. 6 at 8:43 PM

$VIR Company will present complete Week 96 Phase 2 SOLSTICE data on its combination regimen for chronic hepatitis delta (CHD) at the European Association for the Study of the Liver (EASL) Congress - Strong financial position with $809.3 million in cash and investments as of March 31, 2026, excluding $315 million combined Astellas upfront payment1 and equity investment to be received in the second quarter of 2026

0 · Reply

StocktwitsEarnings May. 6 at 8:18 PM

$VIR Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.85 up 3.41% YoY • Reported revenue of -$0.03M down -100.96% YoY • Vir Biotechnology expects its cash, cash equivalents and investments, including effects of the Astellas collaboration and equity financing, to fund operations into the second half of 2028.

0 · Reply

sittingonagoldmine May. 5 at 9:33 PM

$VIR It s time for a repost, as this information is still very valid! +71% since post... :-) Good luck to all long-term VIR bulls!

0 · Reply

justme_DC May. 5 at 9:16 PM

$VIR One of just a few that it feels good to be playing with 'made' money AND it being up beyond that. Holding this for the long run. Would be nice to see that 1 yr avg PT from analysts. DO NOT look at highs and lows and think about what you "would have made" (or lost) ....hmmmmf otherwise would be kicking myself in the a$$

1 · Reply

jewell69 May. 5 at 5:35 PM

$VIR peaks since 7/16/24 my first buy date approx 13.39 on 1/7 and 1/8/2025 11.09 on 4/20/26 the stock had a pretty abrupt (good) gap up 7.45 on 2/23/26 (closing price ) to 9.49 on 2/24/26 tip ranks shows a strong buy 8 buys no holds and no sells a couple of nice pt raises: hc wainwright 15 to 20 on 3/4/26 raymond james 2/24 THE DATE OF THE BIG GAP UP PT from 12 to 19 i bought on 5/5 at 9.9455 700 on a down day (about a -2.6% down as of time bought) now later at 1:34 pm edt, stock is further down (but now much to) 9.92

0 · Reply

jewell69 May. 5 at 5:26 PM

$VIR RE-entry after being away a looooong time b just now 1:22 pm edt 5/5/26 Date Transaction Type Symbol Description Quantity Price Fees & Comm Amount 05/05/2026 Buy VIR VIR BIOTECHNOLOGY INC 700 $9.9455 -$6,961.85 prior 2024 trades Aug-02-2024 Aug-02-2024 500 $4,567.50 $9.14 $4,654.87 $9.31 -- +$87.37 Aug-01-2024 Aug-01-2024 500 $4,902.50 $9.81 $5,089.85 $10.18 -- +$187.35 Jul-15-2024 Jul-16-2024 239 $2,251.38 $9.42 $2,394.23 $10.02 -- +$142.85 Jul-15-2024 Jul-16-2024 300 $2,841.00 $9.47 $3,005.91 $10.02 -- +$164.91

0 · Reply

Kelly12 May. 5 at 12:58 PM

$VIR next data releases ?

1 · Reply

Market Cap	1.48B
Revenue (ttm)	68.56M
Net Income (ttm)	-437.99M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-638.84%
Debt to Equity Ratio	0.00

Volume	1,714,400
Avg Vol	2,046,150
Day's Range	N/A - N/A
Shares Out	168.65M
Stochastic %K	8%
Beta	1.70
Analysts	Strong Sell
Price Target	$20.55